Love your post. Yes the financing is crappy. But pre revenue biotech is risky business.

Cytodyn is not the first company to depend in this type of financing.

Once we have meaningful revenue (income), and an approval (asset) our credit risk shrinks substantially and we will have a much easier time raising capital.

This line of attack by the bashers, and the 13D is transparent.